Vaccitech’s VTP-300 Induced Sustained Reductions of Surface Antigen in Patients with Chronic Hepatitis B Both as a Monotherapy and in Combination with a Single Low Dose of Anti-PD-1

OXFORD, United Kingdom, June 22 (Korea Bizwire) — Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases, cancer, and autoimmune diseases, today announced an update to the interim analysis of safety and efficacy data from the HBV002 [...]

Vaccitech’s VTP-300 was Well-Tolerated and Induced T Cells Against All Targeted HBV Antigens in Both Healthy Volunteers and Patients with Chronic HBV Infection in Interim Analyses

OXFORD, United Kingdom, Nov. 12 (Korea Bizwire) — Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced results from ongoing Phase 1 and Phase 1b/2a clinical trials of VTP-300, an immunotherapy candidate in development for the treatment of CHB infection. Results to date [...]